The blind spot of MSDs
Cut your employees’ sick leave by acting proactively on its invisible causes.
A share of musculoskeletal disorders has a neurological component that standard examinations fail to detect.Dynervolink structures its clinical screening and guides every exposed employee toward the right care, before any risk of long-term leave.
A growing burden
MSDs are, by far, the leading recognised occupational disease in France.
Yet part of their neurological component escapes standard examinations.
90 %
Share of MSDs among recognised occupational diseases Assurance Maladie – Risques professionnels, Rapport annuel 2024
97,4 %
Share of MSDs among occupational diseases in the territorial civil service CNRACL, 2024
30 à 60 %
Dynamic nerve compressions missed by electrodiagnostics Clinical literature — work of Prof. Elisabet Hagert
4,9 Mds€/an
Daily allowances paid in 2024 (workplace accidents and occupational diseases, all risks combined) Assurance Maladie – Risques professionnels, Rapport annuel 2024
The direct cost is measured, the prevention budget committed is documented, and yet part of these disorders persists, with a purely mechanical reading poorly explaining their chronicity. It is this blind spot that calls for developing and grounding a dedicated discipline.
The response to MSDs of nerve origin
A cause that is not named cannot be addressed.
When the neurological component of an MSD is not identified, clinical guidance stays incomplete: the employee goes through one treatment after another without a decisive lever, and the care trajectory lengthens.Dynervolink structures a reproducible clinical screening of this component and guides each employee toward the right care, upstream of treatment.
He who does not know what he is looking for will not understand what he finds.
Claude Bernard, founder of experimental medicine
Without screening
The trajectory that drags on
- The neurological cause stays invisible to standard examination.
- Treatments follow one another without a decisive lever.
- Leave extends, return to work recedes.
With Dynervolink
The cause named, the right guidance
- The nerve component is screened with a reproducible protocol.
- The employee is guided toward the right care.
- The trajectory shortens, ahead of long-term leave.
A simple, effective method
4 steps,
from screening to steering.
A turnkey programme, articulated with your occupational health service and your prevention policy. No additional organisational burden for your teams.
The real risks, department by department
A structured screening of exposed employees produces a precise map of at-risk situations, by department and by role.
The priority situations
Identified cases are confirmed by a clinical assessment performed by a practitioner, following a structured, reproducible protocol.
The causes, and secure the teams
The employees concerned receive appropriate care. They recover and stay operational.
And measure the results
You track the real effect on sick leave and service continuity, through retests and a structured quality-of-working-life report.
What the early evidence shows
Concordant practitioners, patients who attest to it.
Orthopaedic surgeons, a neurologist, a physiotherapist, patients: feedback converges on the clinical value of screening the neurological component. A first exploratory instrumented study documents functional recovery after care.
Electrophysiological assessment objectifies an impairment only in a limited proportion of cases, particularly when the compression is intermittent. Prof. Elisabet Hagert, surgeon · Karolinska Institutet · Aspetar
Strength recovered
as early as month 1
In most patients of a first instrumented series, strength is measured by sensors as improving from the first month after care.
Institute of Dynervology, 2026
Take action
Measure the blind spot of MSDs in your organisation.
A no-commitment scoping conversation to gauge your exposure and the programme suited to your occupational health service.